Research on the Chinese Biosimilar Market (Part 1)

Based on research into the Chinese biosimilar market, Frost & Sullivan has released a related industry report. The report points out that due to differences in industrial structure, the best-selling drugs in the Chinese pharmaceutical market are very different from those in the global market. Among the top 10 best-selling drugs in China in 2018, only two were biologics (insulin), while the other eight were chemical drugs. In the future, the structure of best-selling drugs in China will develop towards a global trend, with more biosimilars becoming blockbuster products leading in sales.